SMAD2 and melanoma: We previously demonstrated that the two pan-CDK/GSK3 inhibitors, flavopiridol [32], [33], [34] and R547 [33], [35], [36] could inhibit the constitutive linker phosphorylation of Smad2 and Smad3 in melanoma cell lines [10].